Industry research
Free alternatives to paid pharma intelligence databases
Free alternatives to paid pharma intelligence databases: what Drugs@FDA, openFDA, ClinicalTrials.gov, EDGAR, CMS and PubMed cover, and where paid tools help.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
Much of what people use pharma intelligence databases for can be done with free public sources: FDA approvals and labels from Drugs@FDA and openFDA, trials from ClinicalTrials.gov, company disclosures from SEC EDGAR, spending from CMS, and literature from PubMed. What the free sources lack is curation: pipeline data on private companies, deal terms, forecasts and a single connected view across all of them.
This post maps common research tasks to the free source that covers each, and is clear about where commercial tools still add value.
What paid databases do
Commercial pipeline and intelligence databases, such as those offered by Citeline, Evaluate, Cortellis and GlobalData, are sold mainly to drug companies, investors, consultancies and service providers. In general terms they collect information from public sources and their own research, standardize it, link drugs to companies, targets and indications, and add analysis.
Their prices, coverage and features vary by product and contract, and this post does not compare them. The useful question for most readers is narrower: which parts of a given task can public data handle on its own?
Free public sources, task by task
| Task | Free source | What it covers |
|---|---|---|
| Approval history and labels | Drugs@FDA and openFDA | Brand-name NDAs and CDER BLAs, approval letters, reviews, labels, supplements |
| FDA program flags | FDA lists for breakthrough, accelerated approval, orphan, priority review | Which approvals used which expedited programs |
| Clinical trials | ClinicalTrials.gov | Registered trials by drug, sponsor, phase, status, sites and posted results |
| Company pipelines and finances | SEC EDGAR | 10-K, 10-Q and 8-K filings with pipeline tables, cash, risk factors and material agreements |
| Safety reports | FAERS via openFDA | Spontaneous adverse event reports by drug and reaction |
| Recalls and shortages | openFDA enforcement and shortages data | Recall class and status, shortage status by product |
| Medicare spending | CMS Part D and Part B Spending by Drug | Gross spending, claims, beneficiaries and average cost per year |
| Literature | PubMed | Abstracts and citations for published research |
Drugs@FDA and openFDA
Drugs@FDA is the official record of brand-name drug approvals. openFDA publishes the same data and much more through free APIs. As of November 2026, this site's catalog built from that data holds 5,899 brand-name applications: 5,412 NDAs and 487 BLAs, of which 3,248 have at least one product still marketed. Generic ANDAs are not in the site's catalog, though Drugs@FDA itself lists about 23,000.
One limit to know: Drugs@FDA covers CDER. Most vaccines, blood products and cell and gene therapies are licensed by CBER and are not in it. For the details of searching it, see how to search Drugs@FDA.
ClinicalTrials.gov
ClinicalTrials.gov is the main public registry of clinical studies. Many trials of FDA-regulated products must be registered, and results must be posted for certain trials. For a well-studied drug the volume is large. Keytruda (pembrolizumab), for example, has 2,877 registered trials naming pembrolizumab, as of November 2026.
Registry entries are only as current as sponsors keep them, and early-stage or non-US studies can be missing.
SEC EDGAR
For listed companies, SEC EDGAR is often the best free pipeline source. Annual reports usually describe each program, its stage and its planned milestones. 8-K filings report material events such as licensing deals, trial readouts and FDA decisions, and material contracts are often filed as exhibits.
The obvious gap is private companies, which generally do not file these reports.
CMS spending data
CMS publishes Medicare Part D and Part B Spending by Drug datasets. They are a public view of real-world use for products used by Medicare beneficiaries. In the 2024 data, gross Part D drug spending totaled $288.7 billion and Part B $60.8 billion. These figures are gross of manufacturer rebates and cover Medicare only, so they are not company revenue.
PubMed
PubMed indexes biomedical literature, and many full texts are free through PubMed Central. It is the standard free place to check published trial results and mechanism research.
How this site combines them
All In Biotech puts these public sources side by side so that the common lookups take one search instead of five:
- /pipeline lists thousands of investigational drugs in Phase 2 and 3 trials, with code names and generic names merged, filterable by sponsor, phase and therapeutic area.
- /companies gathers each company's approved drugs and biologics with the clinical trials it sponsors, by phase.
- /approvals lists 7,565 approvals since 2000, including original approvals and efficacy supplements, with filters for novel drugs and program flags.
- /trials searches ClinicalTrials.gov by drug, area and phase.
- /pdufa is a weekly calendar of announced FDA target action dates, compiled with AI from press releases, filings, FDA's advisory committee calendar and trade press, with a source link for every date.
- /pricing shows Part D and Part B spending by drug.
All data tools on the site are free with no account. The site's methods page, /methods, explains where each dataset comes from and how it is matched.
Where paid tools still add value
Public data has real gaps, and these are where commercial databases tend to earn their place:
- Private companies. Pipeline data for private biotechs is not published in any filing. Commercial providers collect it from press releases, conferences, company contacts and their own research.
- Early and preclinical programs. Many programs are not on ClinicalTrials.gov until a trial starts, and some are never disclosed in detail.
- Deal data. SEC exhibits show some agreements, but many deal terms are redacted or never filed. Curated deal databases standardize upfront payments, milestones and royalties where they are known.
- Forecasts and consensus. Sales forecasts, probability-of-success estimates and peak-sales projections are analysis, not public records.
- Global coverage. Approvals, prices and trials outside the United States are spread across many agencies and languages.
- Connected, cleaned data. Matching a drug code name to its later brand name, its targets, its trials and its company history takes ongoing work. A provider that does it consistently saves time at scale.
For many questions, such as when a drug was approved, what trials exist, what the label says or what Medicare spends, the public record is the primary source, and paid tools are often summarizing it. For questions about private pipelines, deal economics or forecasts, public data alone will not get you there.
A free research workflow
For a listed biotech or a single drug, a reasonable free workflow is:
- Read the company's latest 10-K and recent 8-Ks on EDGAR for its stated pipeline and milestones.
- Search ClinicalTrials.gov for each program to check phase, enrollment, status and dates.
- Check Drugs@FDA for approved products and FDA's program lists for designations.
- Check upcoming FDA action dates and recent approvals.
- Look at Medicare spending for approved products and FAERS for postmarketing safety reports.
- Search PubMed for published results.
The full version of this process is in how to research a biotech company's pipeline with free public data. For a broader list of free drug databases, see the best free drug databases.
Caveats on public data
Public sources are primary records, but they still need care:
- openFDA states that its data should not be relied on for medical decisions and should be treated as unvalidated.
- FAERS reports do not prove that a drug caused an event.
- Medicare spending is gross of rebates and excludes commercial and Medicaid use.
- ClinicalTrials.gov records depend on sponsors updating them.
- AI-compiled calendars such as the PDUFA calendar can miss or misdate events, so check the company's own disclosure.
Used with those limits in mind, free public data covers a large share of everyday drug and company research.
Frequently asked questions
- Is there a free drug pipeline database?
- There is no single free database of every pipeline drug, but ClinicalTrials.gov, SEC filings and FDA's approval and designation lists together cover much of the public pipeline of listed companies.
- What do paid pharma intelligence databases add?
- They curate and connect data, including pipeline details for private companies, deal terms, sales forecasts and analyst commentary, which public sources do not provide in one place.
- Where can I find FDA approval data for free?
- Drugs@FDA and openFDA publish approval histories, labels and letters for brand-name drugs and therapeutic biologics regulated by CDER, free and without an account.
- Is Medicare drug spending data free?
- Yes. CMS publishes Part D and Part B Spending by Drug datasets at data.cms.gov, with figures gross of manufacturer rebates.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.